The field of neuromuscular blocking agents (NMBAs) and their reversal is continually advancing, driven by the need for agents with faster onset, shorter duration, and fewer side effects. While traditional NMBAs like succinylcholine and rocuronium have been effective, they come with limitations such as cardiovascular side effects and reliance on organ function for elimination. To address these issues, new developments have emerged, focusing on improving safety and pharmacokinetics. Among the most promising innovations are chlorofumarates, antagonized by L-cysteine, and novel reversal agents like Calabadion 1 and 2.
Chlorofumarates Antagonized by L-Cysteine
A significant breakthrough in NMBA research is the development of chlorofumarates, a new class of benzylisoquinolinium NMBAs. These agents are metabolized by L-cysteine, an endogenous amino acid, rather than relying on organ metabolism. This eliminates the need for renal or hepatic function, which is especially beneficial for patients with organ impairment. This new mechanism allows for faster recovery and easier reversibility compared to traditional non-depolarizing NMBAs.
The first chlorofumarate to be tested was gantacurium, which had a rapid onset and short duration, similar to succinylcholine. However, its development was halted due to histamine release and associated cardiovascular side effects. Newer chlorofumarates, such as CW002 and CW1759-50, have shown greater promise. CW002 has an onset similar to rocuronium and a duration comparable to atracurium (about 34 minutes). It can be rapidly reversed by L-cysteine within one minute, making it ideal for cases where fast recovery is critical.
CW1759-50, with a very short duration of action (7.4 minutes), resembles succinylcholine but without the cardiovascular side effects or histamine release. It can also be reversed quickly with L-cysteine, making it valuable for short procedures or emergency situations. These agents are currently undergoing clinical trials, with the potential development of a proprietary L-cysteine preparation for NMBA reversal, marking significant progress in NMBA pharmacology.
Calabadion 1 and 2: A New Era of Reversal Agents
Calabadion 1 and 2 are part of the cucurbituril family of molecular containers and represent a new direction in NMBA reversal agents. While sugammadex has been a major advancement, it is primarily effective for steroidal NMBAs like rocuronium and vecuronium. Calabadions, however, can reverse both aminosteroidal and benzylisoquinolinium NMBAs, including cisatracurium, which sugammadex cannot.
Calabadion 1 was the first tested and showed promise in reversing rocuronium and cisatracurium in animal models, though its affinity for rocuronium was lower than sugammadex. The development of Calabadion 2 marked a significant improvement. It has 89 times greater affinity for rocuronium than sugammadex and can effectively reverse profound neuromuscular blockade from vecuronium and cisatracurium. Calabadion 2’s ability to reverse both classes of NMBAs makes it a potentially universal reversal agent.
Like sugammadex, Calabadion 2 works by forming a strong host-guest complex with the NMBA, preventing it from binding to receptors at the neuromuscular junction. Its superior efficacy, especially in reversing deep blockade, addresses a limitation of sugammadex, which is primarily effective for steroidal agents. Calabadion 2 is excreted in the urine, and further human studies are anticipated to confirm its safety and efficacy in clinical settings.
| Agent | Defining property | Reversal and status |
|---|---|---|
| Gantacurium | First chlorofumarate tested; rapid onset and short duration similar to succinylcholine | Development halted because of histamine release and associated cardiovascular side effects |
| CW002 | Onset similar to rocuronium, duration comparable to atracurium (about 34 minutes) | Rapidly reversed by L-cysteine within one minute |
| CW1759-50 | Very short duration of action (7.4 minutes), resembling succinylcholine but without cardiovascular side effects or histamine release | Reversed quickly with L-cysteine; valuable for short procedures or emergencies |
| Calabadion 1 | Cucurbituril molecular container; showed promise in reversing rocuronium and cisatracurium in animal models, though its affinity for rocuronium was lower than sugammadex | The first calabadion tested; Calabadion 2 followed as a significant improvement |
| Calabadion 2 | 89 times greater affinity for rocuronium than sugammadex; reverses profound vecuronium and cisatracurium blockade | Excreted in the urine; further human studies anticipated |
